( ed Dr GregRussell-Jones Apollo's Scie...)Apollo develops needle-free topical vaccine,Health

Apollo's needle-free vaccines would provide a better alternative to injections by:

* Removing the stress of needles - particularly for children;

* Reducing the risk and incidence of needle-stick injuries;

* Reducing the cost of immunisation as the vaccines could be delivered conveniently and easily without medical intervention;

* Being cheaper to store and easier to deploy than injectable vaccines which require refrigeration; and

* Cutting re-use of needles in developing countries, reducing the spread of disease.

Apollo will continue with trials to optimise the tetanus vaccination, and will also investigate the potential of other vaccines.

Apollo has also used its technology to find new ways to deliver other injectable medicines. Last year, the company had notable success with trials on a lotion version of an injected drug for psoriasis.

"We are looking at all the different ways our technology can be used - from anti-inflammatory medicines to the more universal market of vaccines. The tetanus vaccination results pave the way for today's injected vaccines to be rubbed on in the future," said Mr Priest.

For more information: For media enquiries: John Priest, CEO Andrew Huckel Apollo Life Sciences Wilkinson Media 02 9310 1800 / 0419246356 02 8001 8888 / 0402 822 622

www.apollolifesciences.com <http://www.apollolifesciences.com/>

Apollo Life Sciences (ASX: AOP) is a bio-discovery company that has made major breakthroughs in the areas of drug delivery and expression of proteins from human cells. Apollo's combined technologies are expected to lead to more effective and lower cost therapeutics, compared to first generation protein-based drugs.

Fact Sheet

30 April 2007

The importance of ne
'"/>